2024-05-02 11:20:10 ET
Moderna, Inc. (MRNA)
Q1 2024 Earnings Conference Call
May 02, 2024 08:00 A.M. ET
Company Participants
Lavina Talukdar - SVP & Head of IR
Stéphane Bancel - CEO
Stephen Hoge - President
Jamey Mock - CFO
Conference Call Participants
Salveen Richter - Goldman Sachs
Michael Yee - Jefferies
Terence Flynn - Morgan Stanley
Eliana Merle - UBS
Hartaj Singh - Oppenheimer
Gena Wang - Barclays
Luca Issi - RBC Capital
Jessica Fye - J.P. Morgan
Unidentified Analyst -
Evan Wang - Guggenheim Securities
Simon Baker - Redburn Atlantic
Edward Tenthoff - Piper Sandler
Alex Hammond - Bank of America
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Moderna’s First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead.
Lavina Talukdar
Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's first quarter 2024 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investor section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our President; and Jamey Mock, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. I'll now turn the call over to Stéphane.
Stéphane Bancel
Thank you, Lavina. Good morning, or good afternoon, everyone. Thank you for joining us today. I will start with a review of a business, Jamey will then present our financial results. Stephen will review our late-stage clinical programs and I will close by sharing our 2024 commercial priorities and major upcoming milestones. Our COVID vaccine has already impacted hundreds of millions of people. I'm excited by the progress we've made with our pipeline that has the potential to impact many more people. ...
Read the full article on Seeking Alpha
For further details see:
Moderna, Inc. (MRNA) Q1 2024 Earnings Call Transcript